HKD 3.98
(-4.33%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 634.94 Million CNY | 11.91% |
2022 | 567.39 Million CNY | 841.57% |
2021 | 60.26 Million CNY | 0.0% |
2020 | - CNY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 103.21 Million CNY | -26.9% |
2024 Q2 | 103.21 Million CNY | 0.0% |
2023 Q2 | 176.27 Million CNY | 0.0% |
2023 FY | 634.94 Million CNY | 11.91% |
2023 Q3 | 141.19 Million CNY | -19.9% |
2023 Q1 | 176.27 Million CNY | -2.17% |
2023 Q4 | 141.19 Million CNY | 0.0% |
2022 FY | 567.39 Million CNY | 841.57% |
2022 Q3 | 180.18 Million CNY | 0.0% |
2022 Q4 | 180.18 Million CNY | 0.0% |
2021 FY | 60.26 Million CNY | 0.0% |
2020 FY | - CNY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Uni-Bio Science Group Limited | 484.71 Million HKD | -30.993% |
CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 88.071% |